- Telescope Innovations Corp. (CSE:TELI) is leveraging its expertise to advance chemistry process development and crystallization optimization in pharmaceuticals, industrial chemicals, and critical minerals
- Telescope’s Self-Driving Labs (SDLs) integrate AI, robotic-based automation, and advanced chemistry analytical technology
- By leveraging real-time data acquisition and machine learning, SDLs operate continuously, running experiments, analyzing results, and refining processes without the constraints of a traditional work schedule
- Telescope Innovations stock (CSE:TELI) last traded at $0.33
Innovative AI and automation propel scientific progress
Recent advancements in artificial intelligence (AI) emphasize that ingenuity and adaptability, rather than sheer scale, drive innovation.
Companies strategically applying intelligent automation are leading the next wave of scientific progress, accelerating discovery while optimizing efficiency and cost.
Telescope Innovations Corp. (CSE:TELI) is at the forefront of this shift, leveraging its expertise to advance chemistry process development and crystallization optimization in pharmaceuticals, industrial chemicals, and critical minerals. With technology aligned to industry needs and a growing market presence, the company is poised to create significant value for stakeholders in the evolving AI-powered scientific landscape.
Self-driving labs cut time from discovery to market by 10-100x
Telescope’s Self-Driving Labs (SDLs) integrate AI, robotic-based automation, and advanced chemistry analytical technology. By leveraging real-time data acquisition and machine learning, SDLs operate continuously, running experiments, analyzing results, and refining processes without the constraints of a traditional work schedule. SDLs optimize material properties, streamline chemical synthesis, and accelerate process development up to 100 times faster than traditional methods. By enhancing productivity, reducing operational costs, and unlocking new possibilities in scientific exploration, SDLs work alongside researchers to reshape how high-value chemicals and pharmaceuticals are discovered, developed, and scaled for commercialization.
Telescope and global stakeholders drive SDL innovation
Building on its master collaborative research agreement with Pfizer, Telescope continues to refine SDL technology and strategically position its SDLs for deployment within the pharmaceutical industry. Since becoming a Certified Systems Integrator with Universal Robots (UR) in October 2024, the company has enhanced its automation capabilities, integrating collaborative robotics into SDL platforms to offer scalable solutions for global customers.
To further Telescope’s impact, CTO Prof. Jason Hein has actively engaged with leading global institutions, including Seoul National University, the Korean Institute of Science and Technology, and the Korea Advanced Institute of Science & Technology. Through lectures and direct engagements, he has strengthened partnerships with top automation experts, reinforcing the company’s international presence and expanding its network within the world’s most advanced robotics and research communities.
Scaling tech to meet demand
Telescope has expanded its team by 33 per cent over the past six months, strengthening its expertise in chemistry, chemical engineering, robotics, and AI-driven automation. This growth supports the company’s ability to scale SDL platforms and meet the rising demand for automated research solutions in high-value chemical and pharmaceutical industries.
Leadership insights
“Industries today face mounting pressure to innovate faster while reducing costs and resource consumption,” Henry Dubina, Telescope’s CEO, said in a news release. “By integrating AI, robotics, and chemistry, we provide the tools necessary for companies to transform R&D, bringing new products to market with unprecedented speed and efficiency. Telescope is uniquely positioned to deliver scalable, high-impact solutions that create long-term value for both customers and investors. With strong industry adoption and an expanding market presence, we are leading the next wave of automation-driven innovation.”
About Telescope Innovations
Telescope is a chemical and automation technology company developing scalable manufacturing processes and tools for the pharmaceutical and chemical industries. Its products improve experimental throughput, efficiency and data quality.
Telescope Innovations stock (CSE:TELI) last traded at $0.33 and has fallen 4.29 per cent since this time last year.
Join the discussion: Find out what everybody’s saying about this stock on the Telescope Innovations Bullboard, and check out the rest of Stockhouse’s stock forums and message boards.
The material provided in this article is for information only and should not be treated as investment advice. For full disclaimer information, please click here.
(Top image via Telescope Innovations Corp.)
